Phase III trial comparing chemotherapy plus once-daily or twice-daily radiotherapy in Stage III non-small-cell lung cancer 1 1This study was conducted as a collaborative trial of the North Central Cancer Treatment Group and Mayo Clinic. Additional participating institutions included Cedar Rapids Oncology Project CCOP, Cedar Rapids, IA; Meritcare Hospital CCOP, Fargo, ND; Sioux Community Cancer Consortium, Sioux Falls, SD; Geisinger Clinical Oncology Program, Danville, PA (Suresh Nair, M.D.); Rapid City Regional Oncology Group, Rapid City, SD (Larry P. Ebbert, M.D.), Saskatchewan Cancer Centre, Saskatoon, Saskatchewan, Canada; Allan Blair Cancer Centre, Regina, Saskatchewan, Canada (Maria Tria Tirona, M.D.); Scottsdale CCOP, Scottsdale, AZ (Tom R. Fitch, M.D.); Carle Cancer Center CCOP, Urbana, IL (Kendrith M. Rowland, M.D.); Medcenter One Health Systems, Bismarck, ND (Ferdinand Addo, M.D.); Altru Health Systems, Grand Forks, ND (Daniel J. Walsh, M.D.); Siouxland Hematology-Oncology Associates, Sioux City, IA (John C. Michalak, M.D.); and CentreCare Clinic, St. Cloud, MN (Harold E. Windschitl, M.D.).-Reference-Cited by-同舟云学术

Phase III trial comparing chemotherapy plus once-daily or twice-daily radiotherapy in Stage III non-small-cell lung cancer 1 1This study was conducted as a collaborative trial of the North Central Cancer Treatment Group and Mayo Clinic. Additional participating institutions included Cedar Rapids Oncology Project CCOP, Cedar Rapids, IA; Meritcare Hospital CCOP, Fargo, ND; Sioux Community Cancer Consortium, Sioux Falls, SD; Geisinger Clinical Oncology Program, Danville, PA (Suresh Nair, M.D.); Rapid City Regional Oncology Group, Rapid City, SD (Larry P. Ebbert, M.D.), Saskatchewan Cancer Centre, Saskatoon, Saskatchewan, Canada; Allan Blair Cancer Centre, Regina, Saskatchewan, Canada (Maria Tria Tirona, M.D.); Scottsdale CCOP, Scottsdale, AZ (Tom R. Fitch, M.D.); Carle Cancer Center CCOP, Urbana, IL (Kendrith M. Rowland, M.D.); Medcenter One Health Systems, Bismarck, ND (Ferdinand Addo, M.D.); Altru Health Systems, Grand Forks, ND (Daniel J. Walsh, M.D.); Siouxland Hematology-Oncology Associates, Sioux City, IA (John C. Michalak, M.D.); and CentreCare Clinic, St. Cloud, MN (Harold E. Windschitl, M.D.).

Published:2002-10 Issue:2 Volume:54 Page:370-378
ISSN:0360-3016
Container-title:International Journal of Radiation Oncology*Biology*Physics
language:en
Short-container-title:International Journal of Radiation Oncology*Biology*Physics

Author:

Schild Steven E,Stella Philip J,Geyer Susan M,Bonner James A,Marks Randolph S,McGinnis William L,Goetz Steven P,Kuross Steven A,Mailliard James A,Kugler John W,Schaefer Paul L,Jett James R

Publisher

Elsevier BV

Subject

Cancer Research,Radiology Nuclear Medicine and imaging,Oncology,Radiation

Reference17 articles.

1. Cancer statistics 2001;Greenlee;CA Cancer J Clin,2001

2. Non-small cell carcinoma of the lung;Perez Carlos;Cancer Treatment Symp,1985

3. Improved survival in stage III nonsmall cell lung cancer;Dillman;J Natl Cancer Inst,1996

4. RTOG 8808 ECOG 4588, 5-year results of a phase III trial in regionally advanced unresectable non-small cell lung cancer;Sause;Proc Am Soc Clin Oncol,1998

5. Altered fractionated radiation therapy for head and neck carcinomas—The Massachusetts General Hospital experience;Wang;Ann Acad Med, Singapore,1996

Cited by 91 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Stage III Non-Small-Cell Lung Cancer: An Overview of Treatment Options;Current Oncology;2023-03-07

2. Management of Stage III Non–Small-Cell Lung Cancer: ASCO Guideline;Journal of Clinical Oncology;2021-12-22

3. Treatment strategies for unresectable locally advanced non-small cell lung cancer in the real-life ESME cohort;Lung Cancer;2021-12

4. Dose and fractionation schedules in radiotherapy for non-small cell lung cancer;Translational Lung Cancer Research;2021-04

5. Radiotherapy for unresectable locally advanced non-small cell lung cancer: a narrative review of the current landscape and future prospects in the era of immunotherapy;Translational Lung Cancer Research;2020-10